Veru Inc., a biopharmaceutical company traded on NASDAQ under the symbol VERU, revealed plans to participate in the 2026 4th Annual Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day in Boston. The event is scheduled from July 14-16, 2026, where the company will present its latest developments in creating groundbreaking treatments for cardiometabolic and inflammatory conditions. This marks their involvement in the pursuit of innovative medicines for these diseases.